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ARTICLE
Lipoprotein lipase regulates hematopoietic stem
progenitor cell maintenance through DHA supply
Chao Liu1, Tianxu Han2, David L. Stachura3, Huawei Wang 4, Boris L. Vaisman5, Jungsu Kim1,
Richard L. Klemke4, Alan T. Remaley5, Tariq M. Rana 2, David Traver 3 & Yury I. Miller1
Lipoprotein lipase (LPL) mediates hydrolysis of triglycerides (TGs) to supply free fatty acids
(FFAs) to tissues. Here, we show that LPL activity is also required for hematopoietic stem
progenitor cell (HSPC) maintenance. Knockout of Lpl or its obligatory cofactor Apoc2 results
in significantly reduced HSPC expansion during definitive hematopoiesis in zebrafish. A
human APOC2 mimetic peptide or the human very low-density lipoprotein, which carries
APOC2, rescues the phenotype in apoc2 but not in lpl mutant zebrafish. Creating parabiotic
apoc2 and lpl mutant zebrafish rescues the hematopoietic defect in both. Docosahexaenoic
acid (DHA) is identified as an important factor in HSPC expansion. FFA-DHA, but not TG-
DHA, rescues the HSPC defects in apoc2 and lpl mutant zebrafish. Reduced blood cell counts
are also observed in Apoc2 mutant mice at the time of weaning. These results indicate that
LPL-mediated release of the essential fatty acid DHA regulates HSPC expansion and defi-
nitive hematopoiesis.
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Lipoprotein lipase (LPL) is a major lipase in the vasculatureresponsible for hydrolysis of triglycerides (TGs) carried byTG-rich lipoproteins and supplying free fatty acids (FFAs)
to tissues1. Apolipoprotein C-II (APOC2) is an obligatory
cofactor required for LPL activity2. Human patients with APOC2
or LPL deficiency, or deficiency in glycosylphosphatidylinositol-
anchored high-density lipoprotein-binding protein 1 (GPIHBP1),
the LPL vascular anchor, develop severe hypertriglyceridemia and
chylomicronemia1, 3. Recent data indicating that plasma TG
levels predict cardiovascular risk4, 5 have revived scientific com-
munity’s interest in regulation of LPL activity. Study of LPL
activity in mice was initially impeded by post-natal lethality of
systemic Lpl knockout6, 7. Tissue-specific LPL deficiency in adi-
pose tissue resulted in decreased FFA uptake but increased
endogenous synthesis of non-essential FFAs8. Heart-specific Lpl
knockout mice showed cardiac dysfunction despite a compensa-
tory increase in glucose utilization9. Similar cardiac phenotypes
were observed in human patients with LPL deficiency10. Tissue-
specific Lpl overexpression studies suggested that LPL is a key
enzyme responsible for tissue-specific insulin sensitivity and lipid
metabolism11, 12. These studies implicate LPL-mediated TG
hydrolysis and release of FFAs as a key regulator of many phy-
siologic processes in specific tissue contexts. We recently reported
the development of systemic Apoc2mutant mice, characterized by
moderate-to-severe hypertriglyceridemia13, which will be used in
future studies to investigate related phenotypes.
Zebrafish models have emerged as a new powerful tool to study
lipid metabolism14. A hyperlipidemia response to feeding regi-
mens, cholesteryl ester transfer protein (CETP) expression15,
pliancy to genetic modifications, and the optical transparency of
larval zebrafish significantly facilitate these studies. We have
recently reported a chylomicronemia and hypertriglyceridemia
phenotype in apoc2 knockout zebrafish16. In the present study,
we have developed an lpl knockout zebrafish, which have a similar
hypertriglyceridemia phenotype. Remarkably, both apoc2 and lpl
mutant zebrafish display profound anemia and defects in hema-
topoietic stem progenitor cell (HSPC) maintenance and differ-
entiation. Parabiosis of apoc2 and lpl mutants rescues the
defective HSPC expansion in both mutants, indicating the
importance of circulating FFAs. Docosahexaenoic acid (DHA) is
selectively reduced in apoc2 zebrafish mutants. Injections of
exogenous DHA in an FFA form, but not the DHA esterified into
a TG, rescues the HSPC defects in apoc2 and lpl mutants. In
addition, we report anemia in young Apoc2 mutant mice. These
findings may have important therapeutic implications for using
DHA as a dietary supplement to treat anemia and/or expand
HSCs ex vivo.
Results
Loss of apoc2 function in zebrafish results in anemia. Red blood
cells of adult apoc2 mutant zebrafish were characterized by
hypochromia and decreased hemoglobin staining (Fig. 1a), and
the total blood cell count in apoc2mutants was significantly lower
than in WT zebrafish (Fig. 1b). Decreased blood cell numbers,
increased numbers of immature erythrocytes and weak hemo-
globin staining were also observed in 6.3 days post-fertilization
(dpf) zebrafish larvae, but not in 52 h post-fertilization (hpf)
embryos (Fig. 1c–e and Supplementary Movies 1 and 2).
The hematopoiesis phenotype in apoc2 knockout zebrafish
could be due to hyperlipidemia, i.e., high levels of non-hydrolyzed
TG, and/or due to diminished FFA supply. To test whether
hematopoietic defects are a direct result of hyperlipidemia, we
treated apoc2 mutants with lomitapide, an inhibitor of micro-
somal triglyceride transfer protein, which reduces very low-
density lipoprotein (VLDL) formation and is used as a lipid-
lowering drug for treatment of familial hypercholesterolemia
patients. Lomitapide has been reported to reduce hyperlipidemia
in zebrafish as well17. Treatment with lomitapide starting from 2
dpf reduced hyperlipidemia but did not rescue anemia in apoc2
mutant zebrafish (Fig. 1f, g). Similarly, feeding apoc2 mutants a
low-fat diet reduced hyperlipidemia but did not have a significant
effect on anemia (Supplementary Fig. 1 and Fig. 1h).
lpl mutants show defective hematopoiesis. Zebrafish apoc2 is
expressed in the yolk and intestine, but lpl is expressed in the
head and in the caudal hematopoietic tissue (CHT) at 2 dpf, the
latter is a hematopoietic organ during embryonic development
(Supplementary Fig. 2 and Fig. 2a). To further evaluate the role of
LPL activity in hematopoiesis, we mutated the zebrafish lpl gene
using CRISPR-Cas9 and obtained a line with a 2 nt deletion in
exon 4 of the lpl gene, resulting in-frame-shift and a pre-stop
codon. This mutation may result in a truncated mRNA or in-
frame exon skipping and alternative splicing18. To address the
possibility of an alternative splicing, we cloned cDNA from the lpl
mutant and found no alternative transcripts. Furthermore, we
confirmed the presence of only one transcript carrying the 2 nt
deletion that encodes a truncated, loss-of-function Lpl protein
lacking its heparin-binding domain (Fig. 2b and Supplementary
Fig. 3A–C). Interestingly, there was a compensatory increase in
apoc2 expression in the lpl mutants, and a compensatory increase
in lpl expression in the apoc2 mutants (Fig. 2c). However, because
APOC2 does not have a catalytic activity and LPL is not func-
tional without APOC2, both mutants developed hypertriglycer-
idemia (Fig. 2d and Supplementary Fig. 3D–E). Importantly, we
found a similar anemia and hypochromia phenotype in adult and
6.3 dpf larval lpl mutants as those found in apoc2 mutants
(Fig. 2e–i).
HSPC expansion is disrupted in apoc2 and lpl mutants. Similar
to mammals, zebrafish have two major waves of hematopoiesis,
primitive and definitive19–21. The transitive primitive hemato-
poiesis begins at 11 hpf and produces erythroid and myeloid cells
from mesoderm-derived hemangioblasts that persist for the first
several days post fertilization. The definitive hematopoiesis is
attained via HSPCs, which are specified from hemogenic endo-
thelium comprising the ventral aspect of the dorsal aorta (VDA)
at 20 hpf and then migrate to the CHT, where HSPCs undergo
expansion and differentiate into mature blood cells at 2–4 dpf.
Interestingly, apoc2 and lpl mutants did not have any
detectable defects in total blood cell count or hemoglobin content
at 52 hpf, but these measurements were decreased at 6.3 dpf
(Figs. 1c–e and 2i). Because erythrocytes are mostly derived from
primitive hematopoiesis at 52 hpf and largely from definitive
hematopoiesis at 6.3 dpf, we hypothesized that loss of apoc2 may
affect definitive hematopoiesis and thus cause anemia at later
larval stages and in adults. To test this hypothesis, we performed
whole mount in situ hybridization with probes for specific
hematopoietic markers at different stages.
At 20 hpf, wild-type and apoc2 mutant zebrafish had similar
expression of gata1 and beta-globin (erythropoiesis), and pu.1
(myelopoiesis) (Supplementary Fig. 4A), suggesting no detectable
defects in primitive hematopoiesis. Furthermore, wild-type and
apoc2 mutants showed similar expression of HSPC markers
runx1 in the VDA at 26 hpf and cmyb in the VDA and CHT at 52
hpf (Supplementary Fig. 4B), implicating that HSPC specification
and migration were not affected. However, at 80 hpf, expression
of the HSPC markers runx1/cmyb and the blood lineage markers
beta-globin (erythropoiesis) and rag1 (lymphopoiesis) was
significantly decreased in apoc2 mutants compared to wild type
(Supplementary Fig. 4C), suggesting that HSPC expansion and
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differentiation were affected. The HSPC expansion defect was not
due to a moderately delayed angiogenesis in the apoc2 mutant16,
as the defects persisted in angiogenesis-synchronized apoc2
mutant embryos (Supplementary Fig. 5). As expected from
results shown in Fig. 1g, lomitapide did not rescue the defect in
runx1/cmyb and beta-globin expression in apoc2 mutants
(Supplementary Fig. 6). There was no increase in apoptosis in
the CHT region of apoc2 mutants (Supplementary Fig. 7).
Comparing apoc2 mutants with lpl mutants, we confirmed that in
both animal models, the hematopoietic defect commenced at the
HSPC expansion (80 hpf) but not the specification or migration
(26–50 hpf) stage of definitive hematopoiesis (Fig. 3a, b).
To visualize HSPCs in real-time, we used cd41:EGFP
transgenic zebrafish in which HSPCs display weak EGFP
fluorescence and become EGFP bright upon differentiation into
thrombocyte progenitors in the CHT22, 23. In agreement with the
in situ hybridization results, at 54 hpf, there were similar number
of EGFPlow cells in the CHT region of wild-type and apoc2
mutants. When the same clutch of zebrafish was re-examined at
80 hpf, the numbers of HSPCs (EGFPlow) were significantly
decreased in the CHT region of apoc2mutants when compared to
wild type (Fig. 3c, d). Consistent with the CHT data, numbers of
EGFP-positive HSPCs that migrated from the CHT to the
thymus, where they differentiate into lymphoid cells, decreased
dramatically from 54 hpf to 4 dpf (Fig. 3e, f).
LPL-mediated triglyceride hydrolysis regulates hematopoiesis.
If the hematopoietic defect in apoc2 mutants manifests from 50
hpf to 80 hpf, then restoration of apoc2 function starting at 2 dpf
should rescue the hematopoiesis phenotype. Indeed, injecting the
human APOC2 mimetic peptide CII-a, but not its inactive analog
CII-i, rescued the hyperlipidemia and anemia phenotype at 6.3
dpf (Fig. 4a–d) and, importantly, restored both cmyb/runx1 and
beta-globin expression at 3.3 dpf (Fig. 4e) in apoc2 mutants.
We next investigated whether TG hydrolysis, irrespective
of hypertriglyceridemia, could affect normal hematopoiesis.
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Fig. 1 Anemia in apoc2 mutant zebrafish. a Wright–Giemsa (Hema) and o-dianisine staining of peripheral blood cells from adult (18–20-month-old) male
wild-type (WT) and apoc2 mutant zebrafish. b Quantitative results of peripheral blood cell count (n= 11 for WT and n= 9 for apoc2 mutant groups). c
Representative bright field images and quantitative results of blood cell (yellow arrows) count in the caudal vein (outlined with white dashed lines) of WT
and apoc2 mutants at 52 hpf (n= 8 in WT and n= 9 in apoc2 mutant groups) and 6.3 dpf (n= 11 for WT and n= 13 for apoc2 mutant groups). See also
Supplementary Movies 1 and 2. d Wright–Giemsa staining of blood smears from WT and apoc2 mutants at 52 hpf and 6.3 dpf. Immature erythrocytes
containing larger and less condensed nuclei are indicated with red arrows in a and d. Immature erythrocytes with weaker hemoglobin staining are indicated
with green arrows in a. e o-Dianisine staining of 52 hpf and 6.3 dpf WT and apoc2 mutant embryos. f Effect of lomitapide: WT and apoc2 mutants were
treated with 5 μM lomitapide starting from 2 dpf until embryos were fixed at 6 dpf for ORO staining. Black arrows point to intestinal lipid accumulation and
green arrows to circulating lipids. g Blood cell counts in the caudal vein of WT, apoc2 mutants and apoc2 mutants treated with lomitapide at 6.3 dpf (n= 5
in each group). h Blood cell counts in the caudal vein of 14 dpf WT, apoc2 mutants fed with normal diet and apoc2 mutants fed with low-fat diet (LFD)
starting at 5 dpf (n= 4 in WT and apoc2 mut groups each; n= 5 in apoc2+ LFD group). Scale bars, 20 μm in a, c, and d, 100 μm in e, and 200 μm in f.
Mean ± SEM; ***P < 0.001 (Student’s t test)
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Injection of human VLDL into WT embryos at 2 dpf enhanced
expression of HSPC and erythrocyte markers at 80 hpf, suggesting
that oversupply of the TG substrate for Lpl-mediated hydrolysis
promotes, rather than inhibits, HSPC expansion and erythroid
differentiation in the CHT region at this specific stage (Fig. 4f).
Importantly, VLDL (which carries APOC2), but not LDL (which
does not contain APOC2), rescued the defective hematopoiesis in
apoc2 mutants when injected at 2 dpf (Fig. 4f). However, VLDL
injection did not rescue the hematopoiesis defects in lpl mutants
(Fig. 4f) because these zebrafish did not have functional Lpl to be
activated by VLDL-delivered APOC2.
Together, these data suggest that hyperlipidemia per se does
not cause a hematopoietic defect in apoc2 mutants and that
ineffective plasma TG hydrolysis in apoc2 and lpl mutants is the
cause of defective HSPC expansion and differentiation in the
CHT region.
HSPCs anchor to mesenchymal stromal cells after arrival in the
CHT region and this interaction is crucial for HSPCs main-
tenance and differentiation24. To determine which cell types
express lpl, we sorted out HSPCs and stromal cells from the
zebrafish expressing EGFP driven by the gata2 promoter (HSPCs)
and mCherry driven by sdf1α promoter (stromal cells; Fig. 5a, b).
The sorting results were confirmed by testing mRNA expression
of runx1 and sdf1a in isolated fractions (Fig. 5c). Because there
were 100-fold more stromal cells than HSPCs (Fig. 5b) and
because stromal cells, but not HSPCs, highly expressed lpl
ns
***
0
10
20
30
40
50
C
el
ls
/s
eg
m
en
t
WT apoc2
mut
lpl
mut
C
el
ls
/m
l ×
10
9
0
1.0
2.0
2.5
WT apoc2
mut
lpl
mut
***
***
ns
WT apoc2 mut lpl mut
WT apoc2 mut lpl mut
h
TTACAGGCTGAAATTGATTATCCTTGGGAGAAGCTG
     L    Q     A     E      I     D     Y     P    W    E      K     L     
CRISPR Target sequence
WT zLpl
zLpl protein (514aa)
Lipase domain Heparin-binding domain
LH2 (lipoxygenase homology 2)
CRISPR Target sites
TTACAGGCTGAAATTGA - -  CTTCTTGGGAGAAGCT
     L    Q     A     E      I     D      -     F     L    G     E      A      
CRISPR Target sequence
GG2 2nt
zLpl mutated protein (192aa)
0
0.5
1.5
1.0
2.0
2.5
***
**
***
*
T
ar
ge
t g
en
e/
b-
ac
tin
lpl qPCRapoc2 qPCR
apoc2 mut
lpl mut
WT
1.5
0.5
WT apoc2 mut lpl mut
52
 h
pf
6.
3 
dp
f
WT apoc2 mut lpl mut
S
en
se
A
nt
i-s
en
se
lpl in situ
WT apoc2
mut
lpl
mut
0
2000
4000
6000
8000
P
la
sm
a 
T
G
 (
m
g/
dl
)
Triglycerides
***
ns
Adult
6.3 dpf
i
d e f
g
a b c
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WT, apoc2 and lpl mutants (n= 5 in each group). e Peripheral blood cell count in adult (15-month-old) male WT, apoc2 and lpl mutants (n= 5 in each
group). fWright–Giemsa staining of blood smears from 6.3 dpf WT, apoc2 and lpl mutants. g, h Representative images and quantitative results of blood cell
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(Fig. 5c), we concluded that stromal cells are the major source of
lpl expression in the CHT.
To characterize in vivo the requirement for both Apoc2 and
Lpl in supporting hematopoiesis, we employed a parabiotic
zebrafish protocol25. After fusion of a sdf1α:mCherry or a ahmc:
EGFP transgenic embryo, in which the EGFP is expressed in
the cardiac and skeletal muscle cells at early stages, with a WT
embryo, we found no detectable tissue expression of mCherry
or EGFP in the WT embryo, indicating no stromal or muscle
cell exchange (Fig. 5d, e). Fusion of WT embryos with either
apoc2 or lpl mutants rescued the hyperlipidemia phenotype in
both (Fig. 5f, g), suggesting shared blood circulation in parabiotic
zebrafish. Interestingly, fusing apoc2 mutants with lpl mutants
rescued cmyb/runx1 expression in the CHT region of both
(Fig. 5h). These data suggest that under parabiotic settings,
Apoc2 from the lpl mutant and Lpl from the apoc2 mutant
could reconstitute the Apoc2/Lpl pathway. We thus propose
that the Apoc2/Lpl-mediated release of FFAs into shared
circulation rescues hematopoiesis in both mutants, even though
the Lpl deficiency persists in the CHT niche in lpl mutants
(Fig. 5i).
Free fatty acid DHA regulates hematopoiesis in zebrafish.
Although our data suggest that LPL-mediated hydrolysis of TGs
regulates HSPC proliferation in zebrafish, surprisingly, we did not
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find a reduction in the total levels of FFAs in total body homo-
genates of apoc2 mutants compared to WT (Supplementary
Fig. 8, bottom-right graph). This can be explained by a com-
pensatory FFA synthesis in apoc2 mutants. Indeed, levels of FFAs
that can be made de novo, trended higher or were not changed in
apoc2 mutants. However, levels of DHA (22:6n3), which in zeb-
rafish can only be derived from TG hydrolysis, were significantly
lower in 26 hpf embryos (Fig. 6 and Supplementary Fig. 8).
0
2
4
6
8
Parabiosis - ahmc:EGFP + WT
2 dpf
Parabiosis - sdf1a:mCherry + WT
2 dpf
M
er
ge
sd
f1
α
:
m
Ch
er
ry
ga
ta
2:
EG
FP
CHT region
lp
l /
 b
-a
ct
in
sd
f1
α
 
/ b
-a
ct
in
lpl sdf1α
GFP FITC-A
102
102
103
103
104
104
105
105
m
Ch
er
ry
 P
E-
Te
xa
s 
Re
d-
A
gata2:EGFP/sdf1α:mCherry
HSCs: eGFP+
0.02%
Stromal: mCherry+
2.19%
Trunk: neg
11.92%
WT apoc2 mut
Parabiosis - WT + apoc2 mut
Larvae 1 Larvae 2
WT lpl mut
Parabiosis - WT + lpl mut
Larvae 1 Larvae 2
5 dpf5 dpf
In
di
vid
ua
l
WT apoc2 mut
apoc2 mut + lpl mutapoc2 mut + lpl mut
Pa
ra
bi
os
is a
b
a b
13/13 12/1210/10
4/4 80 hpf
Lpl
Apoc2 FFA
Triglycerides Triglycerides
Apoc2
apoc2 mutlpl mut
VLDL
HSPC HSPC
VLDL
Parabiosis
0
1
2
3
4
5
ru
n
x1
 / 
b-
ac
tin
runx1
HS
Cs
St
ro
ma
l c
ell
s
Tr
un
k c
ell
s
HS
Cs
St
ro
ma
l c
ell
s
Tr
un
k c
ell
s
HS
Cs
St
ro
ma
l c
ell
s
Tr
un
k c
ell
s
0
0.2
0.4
0.6
0.8
1.0
1.2
Bright field view Bright field view
lpl mutf g h
d e
a b c
i
Fig. 5 Parabiosis of apoc2 and lpl mutants rescues defective hematopoiesis. a The CHT region of gata2:EGFP, sdf1a:mCherry double-positive embryos at 2.5
dpf. b Flow cytometry of gata2:EGFP and sdf1a:mCherry positive cells isolated from the CHT region. c RT-qPCR analysis of FACS-sorted gata2:EGFP and
sdf1a:mCherry positive cells, using lpl, runx1 and sdf1α primers. Mean ± SD of two independent experiments. d, e Parabiosis of a sdf1α:mCherry or a ahmc:
EGFP with a WT embryo. Right-hand panels are enlarged segments showed in white quadrangles in left-hand panels. Yellow dashed lines trace WT
embryos’ boundaries. f, g Rescue of hyperlipidemia in apoc2 or lpl mutants by parabiosis with WT embryos. Upper panels: two separated embryos (WT and
apoc2 or lpl). Lower panels: larva 1 and larva 2 from a parabiosis pair (WT with apoc2 or WT with lpl). Black arrows point to ORO staining in the lumen of
blood vessels. h In situ hybridization with runx1/cmyb probe in WT, individual apoc2 and lpl mutants, and parabiotic apoc2 and lpl mutants at 80 hpf. Scale
bars, 50 μm in f, g, and 200 μm in a, d, e and h. i Diagram of lipoprotein metabolism in parabiotic lpl and apoc2 mutants. In the lpl mutant, no Lpl is
expressed. However, VLDL secreted by the lpl mutant (orange) delivers Apoc2 through the shared circulation to the apoc2 mutant, in which Lpl is
expressed but its own VLDL (yellow) contains no Apoc2. VLDL from the lpl mutant compensates lack of Apoc2 in the apoc2 mutant and the reconstituted
Apoc2/Lpl catalyzes hydrolysis of TG to release FFAs into the shared circulation, which in turn rescue the hematopoiesis defect in both mutants
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03775-y ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:1310 | DOI: 10.1038/s41467-018-03775-y |www.nature.com/naturecommunications 7
To investigate whether DHA plays a specific role in HSPC
expansion in the CHT region, we injected DHA, as well as
another n3 polyunsaturated fatty acid (PUFA) eicosapentaenoic
acid (EPA; 20:5n3) or monounsaturated oleic acid (OA; 18:1n9)
(all solubilized with BSA) into apoc2 mutants at 2 dpf. DHA, but
not OA or EPA, rescued red blood cell hypochromia, hemoglobin
levels, blood cell counts, and expression of runx1/cmyb and beta-
globin (Supplementary Fig. 9 and Fig. 7a–c). To test whether
DHA must be in a free fatty acid form (FFA-DHA) in order to
rescue the hematopoiesis phenotype, in a separate experiment, we
injected embryos with FFA-DHA or with tridocosahexaenoin, a
TG with three esterified DHA acyl chains (TG-DHA; delivered as
POPC micelles). FFA-DHA enhanced expression of runx1/cmyb
and beta-globin in WT embryos and rescued hematopoietic
phenotypes in apoc2 and lpl mutants (Fig. 8a). Remarkably,
injection of TG-DHA enhanced runx1/cmyb and beta-globin
expression only in WT zebrafish but did not have any effect on
the phenotypes of apoc2 or lpl mutants (Fig. 8b), which are
defective in TG hydrolysis. POPC alone did not have any effect
on runx1/cmyb and beta-globin expression in WT zebrafish
(Supplementary Fig. 10). Taken together, these results suggest
that DHA is a major functional FFA released from TGs through
the APOC2/LPL pathway that plays an important role in HSPC
expansion during definitive hematopoiesis in zebrafish (Fig. 8c).
Anemia in Apoc2 mutant mice. In mouse bone marrow, HSPCs
reside in a complex niche, including stromal cells26. In in vitro
experiments, stromal cells are used to support HSPCs main-
tenance, proliferation, and differentiation. While APOC2 is
associated with circulating VLDL, LPL is a cell surface-associated
protein highly expressed in tissues dependent on FFA supply for
energy (cardiac and skeletal muscle) or storage (adipose)27–29. To
examine which bone marrow cell types express Lpl, we performed
RT-qPCR and found that Lpl was not expressed in mouse HSPCs
(defined for the purposes of this work as Lin−cKit+ Sca1+) or in
other Lin− bone marrow cells (Supplementary Fig. 11). However,
in agreement with the zebrafish FACS sorting/RT-qPCR data
(Fig. 5b, c), stromal cells capable of HSPC support (OP9 cell line)
expressed high levels of LPL (Supplementary Fig. 11). Thus, the
effect of LPL activity on HSPC maintenance is non-cell
autonomous.
While whole-body LPL knockout mice die soon after birth,
homozygous Apoc2 mutant mice, in which three amino acids are
deleted, survive and develop hypertriglyceridemia (757.5 ± 281.2
mg/dl)13. We found that Apoc2 mutant mice had much less white
and red blood cells compared to wild-type mice, when assessed
at the time of weaning (4 weeks) (Fig. 9a). However, the
profound anemia phenotype was alleviated in adult Apoc2mutant
mice (3–4 months), though mutant mice still had significantly
less white blood cells (Fig. 9b). These data suggest that LPL
activity may have an important role in mammalian hematopoiesis
as well.
Discussion
Our work with apoc2 and lpl mutant zebrafish resulted in an
observation of profound anemia in these LPL activity deficient
zebrafish (Figs. 1 and 2), which was not previously discovered in
relevant LPL mouse models. We found that although primitive
hematopoiesis and early HSPC specification and migration were
not affected in the apoc2 and lpl mutants, there was decreased
HSPC expansion in the CHT niche (Fig. 3a, b). With the cd41:
EGFP transgenic fish line, we found HSPCs, but not differentiated
thrombocytes, were decreased during its expansion in the CHT
region, which resulted in decreased HSPCs migration to the
thymus (Fig. 3c–f). Restoration of Apoc2 function starting at 2
dpf rescued the hematopoietic defects (Fig. 4a–e), confirming the
late onset of the requirement for LPL activity in hematopoiesis.
The CHT niche is highly vascularized, which facilitates delivery of
TG by VLDL. VLDL also carries Apoc2, the activator of Lpl.
Thus, injections of human VLDL, supplying both the TG sub-
strate and the APOC2, rescued the HSPCs defect in apoc2
mutants but not in lpl mutants, and increased hematopoietic
markers in WT zebrafish (Fig. 4f).
Our in situ hybridization data indicated that lpl was highly
expressed in the CHT region (Fig. 2a) and FACS sorting/RT-
qPCR results suggested stromal cells were the major source of lpl
expression (Fig. 5a–c). In agreement with the zebrafish results,
mouse studies demonstrated that stromal cells, but not HSPCs,
expressed Lpl (Supplementary Fig. 11), suggesting that HSPCs
rely on systemic and/or stromal cell-derived LPL activity. The
non-cell autonomous character of LPL activity in regulation of
HSPC maintenance complicates mouse studies because of the
post-natal lethality of systemic Lpl knockout. Although mice with
the complete loss of APOC2 are not available, Apoc2 mutant mice
with a three amino acid deletion, which leads to the retention of
the signal peptide and the lack of APOC2 on TG-rich lipopro-
teins, are viable and show moderate hypertriglyceridemia13,
suggesting this mutation is hypomorphic and that Apoc2 mutant
mice can be used as a model of partial LPL deficiency. The finding
of anemia in young Apoc2mutant mice (Fig. 9a) suggests that our
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discovery of the role of LPL activity in zebrafish hematopoiesis is
relevant to mammalian biology. There is a report of lower
hemoglobin levels and anemia observed in 10 out of 14 infants
with LPL deficiency30, but to the best of our knowledge, there are
no reports of anemia in adult human patients with LPL or
APOC2 deficiency. This is in agreement with our findings of the
anemia phenotype being resolved in adult Apoc2 mutant mice
(Fig. 9b). One reason for anemia resolution in adults could be an
increased expression of other lipases, such as hepatic lipase,
endothelial lipase, or phospholipase A2, which hydrolyze TG or
phospholipid substrates, releasing FFA-DHA into the circulation
to support HPSC maintenance. Changes in diet, from fat rich to
carbohydrate rich, in mammals, but not in zebrafish may also
play a role.
Previous studies have reported a moderate delay in develop-
mental angiogenesis in apoc2 mutant or knockdown zebrafish
embryos, which rapidly recovered in older larvae16, 31. It has been
suggested that increased levels of apoB negatively regulate
developmental angiogenesis in zebrafish31. To evaluate the pos-
sibility that the hematopoietic defects observed in apoc2 mutants
may be due to the increased apoB-driven delay in angiogenesis in
hyperlipidemic zebrafish, we synchronized angiogenesis in WT
and apoc2 mutant embryos and found that the hematopoietic
defects persisted in apoc2 mutants (Supplementary Fig. 5). Fur-
thermore, inhibition of apoB lipoprotein production by lomita-
pide did not rescue anemia in apoc2 mutants (Supplementary
Fig. 6) in which LPL function remained defective. These results
suggest that the LPL deficiency and not delayed angiogenesis or
increased apoB levels is responsible for the hematopoietic defect
in apoc2 mutants. Restoring LPL activity in parabiotic apoc2 and
lpl mutants rescued the hematopoietic defect in both (Fig. 5).
We found that the essential fatty acid DHA was specifically
downregulated in apoc2 mutant embryos (Fig. 6 and Supple-
mentary Fig. 8). This is in agreement with a report that DHA
ru
n
x1
/c
m
yb
β-g
lo
bi
n
20/20 11/11 13/18 12/169/11
19/21
WT apoc2 mut
apoc2 mut
+DHA
apoc2 mut
+OA
apoc2 mut
+EPA
WT apoc2 mut
apoc2 mut
+DHA
apoc2 mut
+OA
apoc2 mut
+EPA
9/9 7/7 7/9 6/66/6
a
WT apoc2 mut
apoc2 mut
+DHA
apoc2 mut
+OA
apoc2 mut
+EPA
0
20
40
60
Ce
lls
/s
eg
m
en
t
***
***
ns
ns
WT
apo
c2 
mu
t
apo
c2 
mu
t
+D
HAapo
c2 
mu
t
+O
A
apo
c2 
mu
t
+EP
A
b
21/21 11/13 17/19 15/16
c
Fig. 7 DHA rescues hematopoiesis in apoc2 mutants. a–c apoc2 mutant embryos were injected with free fatty acid docosahexaenoic acid (DHA), oleic acid
(OA), or eicosapentaenoic acid (EPA) at 48 hpf. a o-Dianisine staining of 6.3 dpf larvae. b Representative bright field images and quantitative results of
blood cell (yellow arrows) count in the caudal vein (outlined with white dashed lines) at 6.3 dpf. Mean ± SEM; n= 10 (WT), n= 8 (apoc2mut, apoc2mut+
OA, and apoc2mut+ EPA), and n= 9 (apoc2mut+DHA). ***P < 0.001 (Student’s t test). c In situ hybridization with cmyb/runx1 and β-globin probes. Scale
bars, 100 μm in a; 50 μm in b; and 200 μm in c
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03775-y ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:1310 | DOI: 10.1038/s41467-018-03775-y |www.nature.com/naturecommunications 9
levels were decreased in the hypothalamus of neuron-specific
LPL-deficient mice32. DHA supplementation increases ex vivo
expansion of CD34+ cells derived from umbilical cord or per-
ipheral blood and enhances generation of megakaryocytes33, 34.
Diets enriched in fish oil have been reported to promote hema-
topoiesis in mice, the effect that the authors attributed to
MMP12-dependent remodeling of the hematopoietic niche35.
Maternal dietary supplementation of n3 PUFAs, which contain
56% of DHA, has been shown to increase numbers of CD34+
hematopoietic progenitor cells36. A clinical trial is under way to
test whether diet supplementation with DHA during the second
to third trimester of pregnancy could improve the viability of
stem cells derived from umbilical cord blood37.
However, as we now understand from our studies, supply of
the essential fatty acid DHA or its precursors with the diet is
necessary but not sufficient to promote hematopoiesis. The
DHA needs to be present in an FFA form to be active in the
hematopoietic niche, but diet-supplied DHA is esterified in
the digestive system to be transported by TG-rich lipoproteins38.
Thus, LPL activity is necessary to release DHA from the TGs.
This is demonstrated in our experiments showing that injections
of DHA in the form of FFA, but not in the esterified TG form,
rescue the hematopoietic defects in apoc2 and lpl mutants
(Fig. 8a, b). Both FFA and TG forms of DHA promote hemato-
poiesis in the WT zebrafish in which Lpl function is preserved
(Fig. 8). The effect seems to be specific to DHA since another
n3 PUFA, EPA, or the monounsaturated OA did not rescue
hematopoietic defect in apoc2 mutants (Fig. 7 and Supplementary
Fig. 9).
The exact cellular mechanism of FFA-DHA-mediated HSPC
maintenance remains to be elucidated. It may include activation
of PPARα/δ or upregulation of genes involved in FAO and
mitochondrial biogenesis39–42. In addition, enzymatic oxidation
of DHA might be important for its function since several enzymes
capable of oxidizing DHA, such as soluble epoxide hydrolase, 12/
15-lipoxygenase, or cytochrome P450 epoxygenase, have been
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reported to regulate HSPCs function43–45. Enzymatic products of
FFA arachidonic acid (20:4n6) oxidation, prostaglandin E2
(PGE2), and epoxyeicosatrienoic acids, have been shown to reg-
ulate HSC homing and engraftment45, 46. Clinical applications for
PGE2 in umbilical cord blood HSC transplantation have been
suggested47, 48. Feeding mice with a mix of n6 and n3 PUFAs,
including DHA, stimulated hematopoiesis and thrombopoiesis, as
well as engraftment of donor cells49.
In summary, our studies uncovered an important role of LPL
activity in regulation of HSPC maintenance and definitive
hematopoiesis. The mechanism includes LPL-mediated release of
the essential fatty acid DHA to support HSPC maintenance.
These findings may have important therapeutic implications,
both in terms of dietary recommendations and in optimizing
conditions for ex vivo HSPC expansion.
Methods
Ethics statement. All animal experiments were performed according to the NIH
guidelines and were approved by the University of California, San Diego Institu-
tional Animal Care and Use Committee (protocols S07266 and S04155). Human
plasma, used for VLDL and LDL isolation, was obtained from normal volunteers
who provided written informed consent according to a protocol approved by the
UC San Diego Human Research Protection Program (project #71402).
Zebrafish and mouse maintenance. Adult zebrafish, wild-type (AB strain) and
apoc2 and lpl mutants (on the AB background), were maintained at 28 °C, 14-h-
light/10-h-dark cycle and fed brine shrimp twice a day. The low-fat diet (LFD) was
prepared by extracting lipid from zebrafish GP100–200 micron larval diet (Brine
Shrimp Direct, Utah) with diethyl ether. Zebrafish embryos or larvae younger than
5 days post fertilization (dpf) were kept at 28.5 °C in E3 solution (5 mM NaCl, 0.17
mM KCl, 0.33 mM CaCl2, 0.33 mM MgSO4). The pigment development of early
larvae was inhibited by adding 0.003% N-phenylthiourea (Sigma, Cat. 222909) to
the E3 medium. apoc2 mutants16 and lpl mutants zebrafish were generated in our
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lab. cd41:EGFP and ahmc:EGFP transgenic zebrafish were kindly provided by
David Traver and Neil Chi (both at UCSD), respectively. Apoc2 mutant mice were
created in Remaley’s lab13 and were fed regular chow diet after weaning. All animal
studies were approved by the University of California, San Diego Institutional
Animal Care and Use Committee.
Wright–Giemsa and o-dianisidine staining. Peripheral blood cells were collected
from euthanized zebrafish by tail amputation in adults and by heart puncture in
embryos or larvae. Blood smears were made on superfrost/plus slides (Fisher,
Cat.12-550-15) and fixed in 100% methanol for 15 s. To visualize erythrocyte
morphology, cells were stained using a Hema3 kit (Fisher Diagnostics, Cat.
123–869, an analog to Wright–Giemsa method). To stain for hemoglobin, cells
were incubated with an o-dianisidine staining buffer (0.6 mg/ml o-dianisidine, 0.01
M sodium acetate, pH 4.5, 0.65% H2O2, and 40% ethanol (vol/vol)) for 15 min in
the dark. The slides were imaged with a BZ9000 Keyence microscope. For the
whole mount o-dianisidine staining, dechorionated and euthanized embryos or
larvae were incubated with the o-diansidine staining buffer for 15 min in the dark,
and the embryos or larvae were photographed with a Leica CTR5000 microscope.
The images shown in Figs. 1 and 2 are representative results from at least two
independent experiments, with at least three embryos or larvae in each group per
experiment.
Peripheral blood cell count. To count blood cells, anesthetized zebrafish embryos
or larvae were laterally mounted in 1.0% low-melting agarose in a 50-mm glass
bottom dishes (MatTek, Cat. P50G-0-14-F) and the blood flow video were recorded
using a BZ9000 Keyence microscope. Three frames were extracted from the video
and blood cells were counted manually in each frame, the average number was used
for statistical analysis. Blood was collected from adult male zebrafish through tail
amputation and peripheral blood cells were counted using a haemocytometer after
1:2000 dilution in PBS.
In situ hybridization probe synthesis. Digoxigenin (DIG)-labeled oligonucleo-
tides were synthesized using an in vitro transcription system (Roche, Cat.
11175025910). gata1, cmyb, runx1, and rag1 probes were synthesized from line-
arized plasmids with T7 polymerase. beta-globin, pu.1, and foxn probes were
synthesized from PCR templates with SP6 polymerase. The PCR templates were
amplified from cDNA with specific primers, which were 5′-cgttgctgtcgttctgttta-3′
and 5′-gatttaggtgacactatagttagtggtactgtcttccca-3′ for beta-globin (beta embryonic
1.1), 5′-atctatcgaccaccaatgga-3′ and 5′-gatttaggtgacactataggcgaaggtgttaatgcaaag-3′
for pu.1 and 5′-agtgtagatggaagtcctgt-3′ and 5′-gatttaggtgacacta-
tagttctccaccttctcaaagca-3′ for foxn. The sequence in italic encodes the SP6
promoter.
Whole-mount in situ hybridization. Whole-mount in situ hybridization (WISH)
was performed as described50. In brief, embryos were fixed in 4% paraformalde-
hyde (PFA) overnight at 4 °C and dehydrated sequentially with methanol in PBST
(25, 50, and 75%) and stored in 100% methanol at −20 °C. On the day of WISH,
embryos were rehydrated in PBST (0.1% Tween-20 in PBS), treated with proteinase
K and re-fixed in 4% PFA. After a wash in PBST, the embryos were incubated with
hybridization buffer (HB), which contains 50% formamide, 5× saline sodium
citrate (SSC), 500 µg/ml torula yeast tRNA, 50 µg/ml heparin, 0.1% Tween-20, and
9 mM citric acid (pH 6.5) for 1 h and then with HB containing DIG-labeled probes
overnight at 68 °C. Afterward, embryos were washed sequentially with 2× SSC in
HB (25, 50, and 75%) and 0.2× SSC at 68 °C, and then with 0.2× SSC in PBST (75,
50, and 25%) at room temperature (RT). After the wash, embryos were incubated
in the blocking buffer (PBST with 2% heat-inactivated goat serum and 2 mg/ml
bovine serum albumin) for 1 h at RT and then with blocking buffer containing an
alkaline phosphatase (AP)-conjugated anti-DIG antibody (Roche, Cat.
11093274910, 1:5000 dilution) overnight at 4 °C. To visualize the signals, embryos
were washed six times with PBST for 15 min and then three times with an AP
reaction buffer (100 mM Tris, pH 9.5, 50 mM MgCl2, 100 mM NaCl, 0.1% Tween-
20) for 5 min at RT. The signals were developed by incubating the embryos with a
BM purple AP substrate (Roche, Cat. 11442074001) or an AP reaction buffer
containing NBT/BCIP substrate (Roche, 11681451001). The reaction was termi-
nated using a stop buffer (1× PBS, pH 5.2, 1 mM EDTA, 0.1% Tween-20) and the
embryos were photographed with a Leica CTR5000 microscope. In situ results
shown in Fig. 2d are representative data from three independent experiments. The
results in other figures are representative data from two to five independent
experiments. The images shown in figures are from the same experiment and the
embryo or larva numbers (presented phenotype/total) in each group are indicated
in the panels.
Live imaging. Anesthetized zebrafish embryos were mounted in 1% low-melting
point agarose (Fisher, BP1360-100) containing 0.02% tricaine (Sigma, Cat. A5040)
and imaged using a BZ9000 Keyence fluorescent microscope.
Embryonic injections. The human APOC2 mimetic peptides C-II-a and C-II-I
were reported in previous work16, 51. Six nl of C-II-a or C-II-i (2 mg/ml), 8 nl of
VLDL (2.1 mg/ml) or LDL (2.9 mg/ml), 10 nl of DHA (docosahexaenoic acid):BSA
(bovine serum albumin) (3 mg/ml:100 mg/ml) or OA (oleic acid):BSA (3.3 mg/
ml:129 mg/ml), or 10 nl of POPC:TG-DHA (2 mg/m l:1.2 mg/ml) or POPC (2 mg/
ml) liposome were injected into 2 dpf stage embryos through the sinus venosus
using a FemtoJet micro-injector (Eppendorf).
Oil red O staining and BODIPY staining. Oil red O (ORO) staining was con-
ducted according to published protocols16. Briefly, embryos were fixed in 4% PFA
for 2 h, washed three times in PBS, incubated in 0.3% ORO solution for 2 h, and
then washed with PBS before imaging. For BODIPY staining, live larvae were
immersed in E3 medium containing 0.1 µg/ml BODIPY 505/515 (Invitrogen, Cat.
D-3921) for 1 h in dark and then rinsed with E3 medium before imaging. The
images shown in figures are representative results from two to five independent
experiments, with at least three embryos or larvae in each group per experiment.
CRISPR-Cas9-mediated Lpl knockout in zebrafish. pT3TS-zCas9 and T7-gRNA
plasmids were from Chen lab52 through Addgene. Following the published pro-
tocol52, nls-zCas9-nls mRNA was synthesized with an mMESSAGE mMACHINE
T3 kit (ThermoFisher, AM1348) and recovered with lithium chloride precipitation.
lpl gRNA was generated using a MEGAshortscript T7 kit (ThermoFisher, AM1354)
and purified using a mirVana miRNA isolation kit (ThermoFisher, AM1560). The
zebrafish lpl genomic target sequence was 5′-ggctgaaattgattatccttGGG-3′, in which
the first 20 nt was the gRNA template and the last 3 nt was protospacer adjacent
motif (PAM) required for CRISPR/Cas9 function. 30 pg lpl gRNA and 150 pg nls-
zCas9-nls mRNA were injected into 1–2 cells stage embryos. Genomic DNA
(gDNA) was extracted from whole embryos or from adult tail tissue using a KAPA
Express Extract Kit (KAPA Biosystems, Cat. KR0383). The gDNA fragment con-
taining the target site was amplified using KOD DNA polymerase (EMD Millipore,
Cat. 71086) and digested with T7 endonuclease (NEB, Cat. M0302). Primers used
for PCR amplification of lpl gDNA fragment were 5′-aacatcagcctcctacacaa-3′ and
5′-tcactcgtttctcatgcgaa-3′.
Quantitative RT-PCR. RNA was isolated from 5 dpf zebrafish embryos using an
RNeasy kit (Qiagen, Cat. 74104) and cDNA was reverse transcribed using an
EcoRry Premix (Takara-Clontech, Cat. 639543). Quantitative PCR (Kapa SYBR
FAST qPCR kit, Cat. KK4602) was performed using a Rotor Gene Q qPCR
machine (Qiagen). Primers used in qRT-PCR were 5′-ggcttctgctctgtatgg-3′ and 5′-
ggctctgaccttgttgat-3′ for zebrafish β-actin, 5′- atgaacaagatactggctat -3′ and 5′-
ttgatggtctctacatatcc-3′ for zebrafish apoc2, 5′-gcacggcagttcattcaa-3′ and 5′- gtca-
gattctaccattccagtt-3′ for zebrafish lpl, 5′-cgtcttcacaaaccctcctcaa-3′ and 5′-
gctttactgcttcatccggct-3′ for zebrafish runx1, and 5′-ccaacagcagcaggtctaa-3′ and 5′-
tggtggtctggtggtctt-3′ for zebrafish sdf1α.
Generation of parabiotic zebrafish embryos. The parabiosis experiment followed
the protocol published in ref. 25. Briefly, embryos for parabiosis were transferred to
a glass Petri dish and dechorionated with forceps at the 256-cell stage. Drops of 4%
methylcellulose were laid in rows at the bottom of a plastic Petri dish and covered
with HCR (116M NaCl, 2.9 mM KCl, 10 mM CaCl2, and 5 mM Hepes) containing
antibiotics (2.5 μg/ml ampicillin, 0.5 μg/ml kanamycin, and 10 U/ml
penicillin–streptomycin). Small wells were made on top of the methylcellulose
drops using the tip of a glass pipette. Then, two individual dechorionated embryos,
which developed to the sphere stage but no later than the dome stage, were
transferred to these small wells and gently pressed together with a tiny round-end
iron needle. At the attaching site of two embryos, a few cells were removed using a
sharp glass micropipette. If necessary, the two embryos were moved again to press
the wounds against each other. To avoid any shaking that could separate the two
blastulae, the attached embryos were left under the microscope for 20–30 min.
Once the attachment was secured, the methylcellulose around the embryos was
removed as much as possible. Finally, the plates were fully filled with HCR con-
taining antibiotics and transferred to a 28.5 °C incubator. Next day, HCR medium
was replaced with E3 medium containing antibiotics and residual methylcellulose
was removed.
Drug treatment. Lomitapide (Cayman Chem, Cat. 10009610) powders were dis-
solved in DMSO at the concentration of 1 mM and embryos were treated with 5
μM lomitapide from 2 dpf to 3.3 dpf. DMSO treatment was used as control.
Gas chromatography – mass spectrometry (GC-MS). Pooled embryos or larvae
at the dome, 26 h post fertilization (hpf), or 6 dpf stages were homogenated in PBS
(10 μl per embryo or larva). Fifty μl of the homogenate was used for free fatty acid
extraction, and free fatty acid GC-MS was conducted at the LIPID MAPS Lipi-
domics Core at UC San Diego53, 54.
Apoptosis assay. Zebrafish embryos (3.3 dpf) were fixed in 4% PFA overnight at
4 °C. Embryos were digested with proteinase K (10 μg/ml) for 30 min and then re-
fixed with 4% PFA at RT for 20 min. After the PBST wash, the embryos were
incubated with TUNEL reaction mixture (In Situ Cell Death Detection Kit,
TMRed, Roche, Cat.12156792910) at 37 °C for 1 h. Positive control embryos were
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digested with Dnase I for 15 min. Negative control embryos were incubated with
Label solution without terminal transferase. After the PBST wash, embryos were
imaged with a BZ9000 Keyence fluorescent microscope.
Preparation of injected materials. C-II-a and C-II-i mimetic peptides51 were
dissolved in PBS to a concentration of 2 mg/ml; VLDL (2.1 mg/ml) and LDL (2.9
mg/ml) were from healthy donors and isolated using a standard ultracentrifugation
protocol in UC San Diego lipid core. DHA:BSA were made by dissolving 12 mg
DHA (Cayman, Cat. 90310), which was first dried under argon, in 4 ml of 100 mg/
ml BSA solution (Sigma, Cat. A8806). Oleic acid:BSA was from Sigma (Cat.
O3008). Fatty acid concentrations were measured using an HR Series NEFA-HR
method (Wako, Cat. 999–34691, 991–34891, 993–35191) and BSA was measured
using Lowry assay (Biorad, Cat. 500–0116). To make POPC:TG-DHA and POPC
liposomes, chloroform solubilized POPC (Avanti, Cat. 850457) and tridocosa-
hexaenoin (TG-DHA) (Larodan Cat. 33–2260) were mixed at 2 mg POPC with 1.2
mg TG-DHA or 2 mg POPC alone. The mixtures were dried under argon in round
bottom glass tubes and then 1 ml PBS was added and incubated at RT for 30 min.
Then, POPC:TG-DHA or POPC in PBS was sonicated in a water bath ultrasound
machine (VWR, Model 75D) three times for 10 min, until the solution became
uniform and translucent.
Mouse complete blood count. Blood samples (~50 μl) were collected into EDTA
tubes (BD, Cat. 365974) from mouse tail. To minimize clotting, the tubes were
flicked immediately after blood collection and the samples were sent to the UCSD
Veterinary Diagnostic Laboratory for CBC analysis within 2 h.
FACS sorting of HSPCs and stromal cells. EGFP and mCherry double-positive
embryos were picked up from progenies of the cross between gata2:EGFP and
sdf1a:mCherry zebrafish at 2.5 dpf. Caudal hematopoietic tissues (CHT) were cut
out and washed with PBS. CHT from about 200 embryos were digested with 1 ml
Trypsin-EDA (Corning, Cat. 25-052-CI) containing 10 μg/ml collagenase (Wor-
thington Biochem, Cat. MOP123) at 35 °C. FBS (Omega Science, Cat. FB-01) was
added to a final concentration of 5% to stop the reaction. Cells were spun down at
350 × g for 5 min, re-suspended in PBS and stained with Aqua-LIVE/DEAD kit
(ThermoFisher, Cat. L34965). Cells were spun down, washed once with PBS, and
re-suspended in 0.5 ml staining buffer (PBS containing 0.5% BSA). After filtration
through a 70 μm cartridge, cells were sorted using a BD FACSAria II machine. Live
EGFP single-positive cells, mCherry single-positive cells, and EGFP/mCherry
double-negative cells were defined as HSPCs, stromal cells, and trunk cells,
respectively.
Bone marrow cells were collected from mouse femur and tibia and depleted
from red blood cells with a red blood cell lysis buffer (eBioscience, Cat. 00–4333).
Cells were spun down at 350 × g for 5 min, re-suspended in the staining buffer to
10 million per ml, and stained with Lin-APC (BD, Cat. 55807, 1:1000 dilution),
cKit-PE (eBioscience, Cat. 12-1172-82, 1:300 dilution), and Sca1-PEcy7
(eBioscience, Cat. 25-5981-81, 1:2500 dilution) antibodies on ice for 15 min. Cells
were spun down and washed once with PBS and re-suspended in the staining
buffer to 3–5 million per ml. Cells were sorted using a BD FACSAria II machine
and fluorescence minus one (FMO) and single stain controls were used to calibrate
the threshold in the FACS sorting. Cells with lineage negative staining (Lin−) were
further selected for positive Sca1 and c-Kit staining (Sca1+ and c-Kit+), and these
cells were defined as LSK.
Data availability. The authors declare that all data supporting the findings of this
study are available within the article and its supplementary information files or
from the corresponding author on reasonable request.
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